Navigation Links
New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
Date:11/13/2007

-- Data Presented at Anti-Angiogenesis Conference Shows R84, the Selective

Human Anti-VEGF Antibody Developed by Peregrine in Association with Affitech, Is Equivalent to Avastin in Inhibiting Growth of Established

Tumors in a Preclinical Breast Cancer Model --

-- R84 Is Being Advanced as a Potential Clinical Candidate --

BOSTON and TUSTIN, Calif., Nov. 13 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) a clinical stage biopharmaceutical company developing targeted monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today reported that preclinical data presented at IBC's 5th Annual International Anti-Angiogenesis Conference showed that its anti-VEGF antibody R84 was as effective as Avastin(R) (bevacizumab) in inhibiting tumor growth in a mouse model of human breast cancer. R84 is a selective, fully human monoclonal antibody that blocks the cancer-promoting agent vascular endothelial growth factor (VEGF). R84 selectively blocks VEGF from binding only to VEGF receptor 2 (VEGFR2), while non-selective agents such as Avastin block binding to both VEGFR2 and VEGF receptor 1 (VEGFR1). Selective anti-VEGF agents may have potential advantages over non-selective approaches and Peregrine is now assessing R84 as a candidate for clinical development. R84 is a product of the collaboration between Peregrine and antibody developer Affitech AS of Oslo, Norway.

The data demonstrating the potential anti-cancer efficacy of R84 in xenograft models of human cancer was part of a presentation by Dr. Rolf Brekken, assistant professor of surgery and pharmacology and Effie Marie Cain Scholar in Angiogenesis Research at UT Southwestern Medic
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
2. IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients
3. Study Confirms That New Protocol Shortens the Time It Takes to Open Blocked Arteries for Heart Attack Patients
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
8. Video: New Research Discovers Independent Brain Networks Control Human Walking
9. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
10. Enrollment Begins on Human PK Study for Medidur(TM) FA
11. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... y PARÍS, 24 de mayo de ... ), un destacado desarrollador y fabricante de herramientas ... la diagnosis y tratamiento de la enfermedad vascular ... del ensayo ADVISE ( Ad enosine V ... E valuation) II durante la sesión de ensayo ...
(Date:5/23/2013)... 23, 2013 Amgen (NASDAQ: AMGN ) ... Healthcare Conference on Thursday, May 30, 2013, at the Westin ... 9:20 a.m. Eastern Daylight Time. Arvind Sood ... at the conference. Live audio of the presentation can be ... , under Investors. A replay of the webcast will also ...
(Date:5/23/2013)... May 23, 2013 Nephros, Inc. (OTC Bulletin ... device company that develops and sells high performance liquid ... rights offering.  In addition, the concurrent temporary reduction in ... on May 17, 2013. Nephros estimates that ... the rights offering.   A portion of the proceeds will ...
Breaking Medicine Technology:Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4
(Date:5/24/2013)... News) -- The number of U.S. patients admitted ... in an emergency room has increased by nearly ... study, conducted by researchers at the George Washington ... in Washington, D.C., found that patients wait five ... being admitted to the ICU. The researchers said ...
(Date:5/24/2013)... Bay, Australia (PRWEB) May 24, 2013 ... show off their favorite sunglasses all while learning ... longer with replacement lenses. Contestants only need ... wearing their sunglasses and "like" The Sunglass Fix ... winning Sunglass fix is the largest lens ...
(Date:5/24/2013)... aortic valve implantation (TAVI) is effective and safe in ... results from a multicentre Asian registry reported at EuroPCR ... a treatment option for selected patients with symptomatic severe ... North American or European centres," Paul Chiam, senior consultant ... conference. He explained that it is unknown whether the ...
(Date:5/24/2013)... In a coup that surely made other ... of the Estetica Institute of the Palm Beaches performed eye ... popular morning show, “The Mo & Sally Morning Show.” The ... satisfaction with the results, giving Dr. DeLange and the team ... Beach Gardens, very valuable free publicity. , Dr. DeLange, the ...
(Date:5/24/2013)... 2013 CBT News.com recently announced the addition ... web-based retail automotive industry news organization with 12 years experience ... to join a group that’s so forward-thinking in their approach,” ... online video content is on the rise.” , Atlanta born ... and segued into advertising at Cycle News and Boating World. ...
Breaking Medicine News(10 mins):Health News:Sharp Rise in ICU Admissions From U.S. Emergency Rooms 2Health News:Break the Sunglass Mold – Reuse 'Em, Don’t Toss 'Em then Enter the SunglassFIX Photo Contest to Win 2Health News:Registry confirms TAVI efficacy and safety in Asian patients 2Health News:Dr. Greg DeLange of the Estetica Institute Recently Performed Eye Surgery on Both Members of Popular Morning Radio Team 2
... HealthDay Reporter , WEDNESDAY, July 27 (HealthDay News) ... emotional or behavioral issues often face tough social and ... , Tracking the progress of more than 1,450 students ... U.S. researchers found that one-third coped with special health ...
... research out of UCLA has found that Latinos living in ... the country are far less likely to spend for ... they do spend than the white population. ... they stay in the country, spending disparities remain large over ...
... discoveries in the field of cognitive neuroscience hold great ... a significant gap between such scientific discoveries and the ... New York Academy of Sciences and the ... conference on September 22-24, 2011 in Aspen, Colorado, ...
... BROOK, Ill. (July, 27, 2011) Using computed tomography (CT), ... lungs of patients with chronic obstructive pulmonary disease (COPD) that ... worsen. Their findings are published online in the journal ... the air sacs of the lungs, and is a leading ...
... risk factor for COPD, but have not accounted for ... Women,s Hospital, the University of Colorado, and National Jewish ... from the COPD Gene Study, capturing parental smoking and ... findings noted a strong risk factor for COPD when ...
... Brigham and Women,s Hospital (BWH) uses a new imaging technique, ... that are activated when patients with low back pain have ... published in the August issue of the journal Anesthesiology ... providing tools to objectively describe someone,s chronic pain which is ...
Cached Medicine News:Health News: Special Needs Kids Bullied More, Fare Poorly at School 2Health News: Special Needs Kids Bullied More, Fare Poorly at School 3Health News:Big gap exists on health care spending between Latinos and whites, study finds 2Health News:Conference: Improving K-12 education with cutting-edge cognitive neuroscience research 2Health News:CT shows changes in lungs associated with COPD flare-ups 2Health News:New imaging technique captures brain activity in patients with chronic low back pain 2
Anterior Chamber Needle, 30 g. Angled. 5 mm angled tip. Overall length 20 mm. 5/box....
Anterior Chamber Needle, 23 g. Angled. 7 mm angled tip. Overall length 23 mm. 5/box....
Anterior Chamber Needle, 20 g. Angled. 7 mm angled tip. Overall length 23 mm. 5/box....
Hydrodissection / Aspiration Cannula, 25 g. Angled with right hook. 10 mm angled shaft with 2.5 mm right hook tip. Overall length 20 mm. 5/box....
Medicine Products: